Lessons from mouse models of Graves’ disease

A. Eckstein1 · S. Philipp2 · G. Goertz2 · J. P. Banga2,3 · U. Berchner-Pfannschmidt2

Received: 26 November 2019 / Accepted: 7 April 2020 / Published online: 12 May 2020
© The Author(s) 2020

Abstract
Graves’ disease (GD) is an autoimmune condition with the appearance of anti-TSH receptor (TSHR) autoantibodies in the serum. The consequence is the development of hyperthyroidism in most of the patients. In addition, in the most severe cases, patients can develop orbitopathy (GO), achropachy and dermopathy. The central role of the TSHR for the disease pathology has been well accepted. Therefore immunization against the TSHR is pivotal for the creation of in vivo models for the disease. However, TSHR is well preserved among the species and therefore the immune system is highly tolerant. Many differing attempts have been performed to break tolerance and to create a proper animal model in the last decades. The most successful have been achieved by introducing the human TSHR extracellular domain into the body, either by injection of plasmid or adenoviruses. Currently available models develop the whole spectrum of Graves’ disease—autoimmune thyroid disease and orbitopathy and are suitable to study disease pathogenesis and to perform treatment studies. In recent publications new immunomodulatory therapies have been assessed and also disease prevention by inducing tolerance using small cyclic peptides from the antigenic region of the extracellular subunit of the TSHR.

What is Graves’ disease?/Pathogenic mechanism of Graves’ disease

Autoimmunity to the thyroid-stimulating hormone receptor (TSHR) plays the central role for the pathogenesis of Graves’ disease (GD) [1]. Binding of stimulating anti-TSH-receptor antibodies (TRAb) leads to hyperthyroidism, which is uncontrolled by the pituitary [2]. The consequences of increased production of thyroid hormones are manifold: weight loss, tachycardia, hyperthermia to name only a few. The TSH receptor is also expressed by orbital fibroblasts [3]. Binding of TRAb to orbital fibroblasts leads to hyaluronan production and differentiation to adipocytes and myofibroblasts [4–6]. The consequence is the increase of orbital fat and also fibrosis of the orbital connective tissues, especially the extraocular muscles. In the confines of the bony orbit, this leads to proptosis, swelling of the soft tissues and to restricted eye movements with diplopia [7]. The stimulation of the TSHR on the orbital fibroblasts leads to a pathologic cross talk between the TSHR and the Insulin-like growth factor 1 receptor [8–10], which plays an important role for the stimulation of all the processes induced.

Besides the proliferative stimulation of the orbital fibroblasts, inflammatory cytokines are released which act to recruit additional immune and inflammatory cells to the orbit [11, 12]. The CD40 expression of orbital fibroblasts allows direct interaction with infiltrating T cells with potential additional cytokine release [13]. Since the inflammatory/proliferative processes take place in a bony limited space—the orbit—tissue hypoxia contributes to the pathogenic mechanisms depending on the grade of compression which is caused by the tissue volume changes [14].

Due to many influencing factors genetic and environmental Graves’ disease has highly variable phenotypes and time relations between the onset of thyroid and eye disease.

Induction of an animal model for Graves’ disease—break tolerance to TSHR

The development of animal models for Graves’ disease were accelerated with the sequencing of the TSHR and
Fig. 1 Immunization against the TSHR was realized by inducing in vivo-expression of the TSHR by using different approaches.

- Injection of h/m TSHR expressing cells
  - Fibroblasts: Shimojo et al. 1996, Kita et al. 1999, Anda et al. 2003, Banga et al. 2007
  - B-cells: Kaithamana et al. 1999, Landa et al. 2004
  - Dendritic cells: Kita-Furuyama et al. 2003, Mizutori, 2006

- Adjuvans/Immunemodulation:
  ...Aluminium phosphate, Pertussis toxin, cardiotoxin, Electroevaporation and CD25-depletion

- Genetic immunisation
  - h/m TSHR coding Plasmids (± hTSHR-primed T-cells)
    - Wildtyp TSHR:
      - Costagiolia et al. 1994, 1998
      - Mary et al. 1999
      - Costagiolia et al. 2000
      - Baker et al. 2005
      - Ho et al. 2007
    - h TSHR a-subunit plus electroporation
      - Zhao et al. 2011, Johnson et al. 2012, Moshkelgosha et al. 2013, 2018, Berchner-Pfanns. et al. 2016, Flögel et al. 2018, Schluter et al. 2018 (2x), Piöhn et al. 2018
    - m TSHR a-subunit
      - Schluter et al. 2018
    - Adenovirus with coding TSHR
      - h/m Wildtype TSHR
        - Nagayama 2002
      - h TSHR a-subunit
        - Chen et al. 2003, 2004
        - Gilbert et al. 2006, Land et al. 2006, Mizutori et al. 2006, Saiioh et al. 2006, Liu et al. 2017, Jansson et al. 2017, Ungerer et al. 2017, Holthoff et al. 2018, Zuo et al. 2019, Foßbender et al. 2019, Tang et al. 2019
    - Subsequent transfer of mTSHR-reactivated splenocytes
      - Nakahara 2012

consequently the availability of recombinant TSHR DNA, which made it amenable to prepare substantial quantities of recombinant TSHR protein or synthetic peptides for active immunization. In addition, the development of innovative techniques leading to in vivo expression of the receptor was the key to successful models of Graves’ disease [15].

Immunization against the TSHR was realized by inducing in vivo expression of the TSHR by using different approaches (see Fig. 1): (1) Injection of TSHR-expressing cells, (2) genetic immunisation using TSHR-expressing adenovirus, and (3) genetic immunisation by using plasmids encoding for the TSHR. Injection of TSHR-expressing cells delivered less solid induction of autoimmunity and was therefore abandoned—summary in [16].

Nagayama et al. described a mouse model of Graves’ disease that is based on genetic immunization by TSHR-adenovirus and was tested on different strains of inbred mice [17]. Female BALB/c mice reached the highest disease rates. Based on the observation of Chazenbalk et al. [18] that TRAbs in Graves’ disease preferentially recognize the free A subunit of the TSHR, Chen et al. [19] modified the adenovirus model concerning the antigen. It was shown that immunization by Adenovirus-TSHR289, which encoded only the A subunit of the human TSHR-induced hyperthyroidism and TRAb to a greater extent than immunization by adenovirus carrying the full length TSHR wild type. Incidence of hyperthyroidism was reported to be up to 86%. This model has been shown to be highly reproducible—summary in [16] and is widely used. Several modifications have been developed like additional depletion of CD25+ T cells [20].

Genetic immunization by using plasmids encoding the TSHR also has a long history of use and was first published by investigators from Brussels, who were also able to demonstrate some disease transfer using TSHR-primed splenocytes [21–23]. Different plasmids, even encoding TSHR genes with activating mutations [24] have been used. However, as with protocols using adenovirus immunization, the success for genetic immunization with plasmids was greatly improved by employing the TSHR-A-subunit, rather than the holoreceptor, and a special technique electroporation [25]. This approach resulted in a high incidence of induced hyperthyroidism accompanied by a sustained antibody response to TSHR. Importantly, histological investigation of orbital tissue gave the first indication of orbital inflammation and fibrosis in the model [26]. The model is highly reproducible and the pathological features of orbital remodeling were more reminiscent of those present in Graves’ orbitopathy (GO) patients [27–29].

Today there are two potent techniques for inducing in vivo models of GD applied—adenoviruses and plasmids—ready to do extensive studies on pathogenesis to identify new targets for therapy and to perform treatment studies.

**Actual pathogenetic studies with GD/GO in in vivo models**

To follow inflammation and remodeling of the orbital tissue in a noninvasive manner in vivo, we have established a powerful imaging strategy with a 9.4 T micro imaging system. Beyond anatomical hydrogen-1 (1H) MRI, we employed transverse relaxation time (T2) mapping for visualization of oedema, chemical exchange saturation transfer for detection of hyaluronan, and fluorine-19 MRI for tracking of in situ-labeled...
immune cells after intravenous injection of perfluorocarbons. Fluorine-19 MRI-based visualization of orbital inflammation exhibited the highest significance level to discriminate between GO and control mice and showed the best correlation with the clinical score [28].

The induced Graves’ disease displays a variable phenotype, as occurs in GD patients. It is similar in the in vivo model. It is therefore reasonable to test the influence of environmental factors on the disease phenotypes.

It is now widely known that the gut microbiota has considerable influence on our immune system.

Under the hypothesis that gut microbiota may modulate clinical presentation of disease a two center study was performed. Variations in a TSHR-induced model of GD/GO in 2 independent centres, correlated with gut-microbiota diversity. A significant positive correlation between the presence of Firmicutes and orbital-adipogenesis specifically in TSHR-immunized mice was observed [30].

To investigate further, in subsequent experiments we modified the gut microbiota of the female BALB/c mice using antibiotic vancomycin, probiotic or human (from patients with GO) faecal material transfer prior to immunization. The reduced thyroid and orbital pathology, combined with diminished lymph node CD25+ T cells, in vancomycin treated mice support a role for the gut microbiota in promoting GO [26].

It appears that these findings contrast an earlier study, in which depletion of CD25+ T cells increased disease susceptibility [20]. The two studies may indicate that relative changes in CD25+ T-cell numbers (either depletion or reduction) can have different consequences. However, we cannot exclude that the relative CD25+ T-cell numbers declined during the antibiotic treatment as a result of an ongoing immune suppression. Moreover, the studies only report the percentage of CD25+ T cells and did not access functional activity. It is known that CD25+ T cells exert regulatory functions but can also (re)gain effector functions. However, it is well accepted that T-cell populations expressing the transcription factor forhead box protein 3 (Foxp3) constitute T-cell lineages with suppressive functions [31, 32]. With respect to this, our study is limited since it did not investigate Treg populations expressing Foxp3 which could have been differently affected by the antibiotic treatment. A few studies addressed the role of Treg expressing Foxp3 in GD/GO mouse models [33–36]. In a GD mouse model induced by adenovirus Ad-TSHR289, the frequencies of CD4+CD25+Foxp3+ Treg cells were decreased [34, 36]. More recently, we modulated T-cell proportions in our GD/GO model by treatment with the immunomodulatory drug fingolimod. Of note, the suppression of TSHR autoimmunity was accompanied by a decrease in CD25+ T cells while subsets CD25+Foxp3+ Tregs were increased [35]. Whether the observed changes in Treg proportions represent their role in improving TSHR autoimmunity remains to be proven by further studies addressing the functional activity of the different T-cell subsets in the model.

Another group studied the influence of 5α-dihydrotestosterone (DHT) a potent bioactive androgen in the mouse model. It could be shown that DHT can alleviate the severity of GD by downregulating pro-autoimmune T helper 1 cells in female BALB/c mice. The protective influence was dose dependant [37]. In a follow-up study it could be shown that DHT acts on cytokines and oxidative stress markers. Thyroid hormones were significantly reduced in DHT treated GD mice in comparison to the untreated control group. In addition, DHT attenuated thyroid oxidative injuries in GD mice, as shown by decreased total antioxidation capability (TAOC), superoxide dismutase (SOD) and the level of malondialdehyde (MDA). The levels of immunosuppressive cytokines (TGF-β, IL-35) in DHT group were significant higher compared with the control group [35].

Treatment studies with in vivo models of GO—translation into the clinic

Recently, a few trails testing immunomodulatory strategies for treatment of GD have been published.

One of the tested therapeutic approaches was to administer small amounts of antigens over time to reinstates immune tolerance. Ungerer et al. aimed to induce B- and T-cell anergy by using long and short cyclic peptides derived from the first and eighth cylindrical loops of the leucin-rich repeat domain of the TSHR. The peptides were tested in a mouse model of Graves’ disease where TSHR autoimmunity was induced by long-term protocol of four-weekly immunizations with adenovirus coding for the TSHR A-subunit (Ad-TSHR289). The short cyclic peptides from the first leucin-rich repeat loop turned out to be most efficient in reducing thyroid size, serum thyroxine levels, retro-orbital fibrosis, and tachycardia. In immunologically naïve mice, administration of the peptides did not induce any immune response.

Therefore, cyclic peptides may provide an additional therapeutic option compared to existing drugs or interventions [38, 39].

Another group attempted tolerance induction with the use of synthetic peptides that mimic naturally processed CD4 T-cell epitopes termed “apitopes,” short for antigen-processing independent epitopes. The CD4 T-cell apitopes from TSHR were first tested in an HLA-DR3 transgenic mice and in the Ad-TSHR289 mouse model. The apitopes were able to reduce TSHR-induced proliferation of splenocytes in HLA-DR3 transgenic mice.
In the Ad-TSHR289 mouse model a preventive treatment schedule was applied meaning application of two different mixtures of immunodominant epitopes before the induction of autoimmunity with the Ad-TSHR289. Both mixtures of epitopes were able to suppress TSHR autoimmunity antibody production and reduction of thyroid hormone levels [40].

The animal study was followed by a phase I human trial with the most efficient mixture of epitopes ATX-GD-59. ATX-GD-59 was given in a dose escalation protocol in the first 8 weeks and in full dose another 10 weeks. Patient with untreated mild-to-moderately severe Graves’ hyperthyroidism were included in the study. Levels of free thyroid hormones decreased in 70% of subjects receiving the medication and ATX-GD-59 was safe and well tolerated. Further studies are needed for this novel treatment rational for Graves’ hyperthyroidism [41].

Tolerance induction was not disrupted by current drug treatments. These results demonstrate that antigen-specific immunotherapy with epitopes from TSHR is a suitable approach for treatment of GD [40].

Another recent in vitro study suggested that sphingosine-1-phosphate (S1P) signaling is involved in orbitopathy [13]. In a follow-up study the immune modulatory potential of S1P receptor antagonist fingolimod (FTY720) was explored in a murine model for Graves’ disease [33]. In the model TSHR autoimmunity was induced by immunization with a plasmid encoding for the A-subunit of the TSHR. Fingolimod was orally administered preventively during disease onset or therapeutically after disease onset. Administration of fingolimod during disease onset completely prevented the formation of TSHR-stimulating autoantibodies. Intervention after disease onset rarely reduced TSHR-stimulating autoantibodies. However these therapeutically treated animals showed milder manifestation than the animals in the untreated control group. Clinically they showed less increase of body temperature, weight gain and tachycardia. In mice weight gain is a sign of hyperthyroidism most likely caused by a higher food intake by the hyperthyroid mice [42].

The therapeutically treated mice developed less often overt autoimmune hyperthyroidism characterized by less elevated serum thyroxine levels, less hyperplastic thyroid morphology accompanied by T-cell infiltration. In mice weight gain is a sign of hyperthyroidism most likely caused by a higher food intake by the hyperthyroid mice [42].

The therapeutically treated mice developed less often overt autoimmune hyperthyroidism characterized by less elevated serum thyroxine levels, less hyperplastic thyroid morphology accompanied by T-cell infiltration. Importantly, examination of orbital tissue showed significant amelioration of orbitopathy manifestations by reduction of T-cell infiltration, adipogenesis and hyaluronan deposition [35].

Analysis of total disease outcome revealed that treatment during disease onset protected animals against autoimmune hyperthyroidism and orbitopathy. Of note, therapeutic intervention after disease onset suppressed disease in half of the animals and in the other half disease remained at mild stages (see Fig. 2). Based on the results of that study a clinical trial to investigate the immunologic and clinical benefits of early treatment with S1P-based drugs in Graves’ disease can be suggested [33].

---

**Fig. 2** Treatment with fingolimod in a preclinical mouse model: animals were treated with the first immunisation during disease onset (preventive treatment; TSHR + prev) or after the last immunisation with TSHR extracellular coding plasmid (therapy in the state of fully developed disease; TSHR + ther). Results of different parameters were combined and analyzed by Z-scoring for autoimmune hyperthyroidism (GD—including results for fT4, TSAb [stimulating anti-TSH-receptor antibodies], bodyweight, body temperature, CD3 infiltration of the thyroid), orbitopathy (GO—including brown fat content, CD3 infiltration in the orbital tissues, Hyaluronan acid content) or total disease (GD + GO). Percentages of mice that have developed either no (Z-score < 0, blue), mild (Z-score > 0 but < 1, red) or moderate/severe (Z-score > 1, yellow) disease are indicated.
Conclusion

The development of an animal model for Graves’ disease is dependent on the immunization against the human TSHR, providing compelling evidence for the TSHR being the primary autoantigen of the disease. Tolerance against the evolutionary conserved TSHR can be broken by introducing plasmids or adenoviruses encoding for the TSHR extracellular into the animal body. The currently available models develop the whole spectrum of Graves’ disease—autoimmune thyroid disease and orbitopathy. A difficulty is the variable clinical phenotype, which is found in humans as well as in the animal models, making higher numbers of animals per experiment necessary. However, the similarity between human disease and the animal model allows the study of disease pathogenesis, the natural history of the disease and events that underlie the continued progression of the autoimmune response to the orbital components in GO. Moreover, most important the animal models are suitable to perform treatment studies.

In one of the treatment studies, fingolimod has been used which causes the internalization of S1P receptors, which sequesters lymphocytes in lymph nodes, preventing them from moving to sites of inflammation. Fingolimod has been shown to prevent the disease completely and it is also therapeutically efficient in overt Graves’ orbitopathy/hyperthyroidism. Another trial addressed tolerance induction by using small cyclic peptides from the antigenic region of the extracellular subunit of the TSHR. The administration of these cyclic peptides reduced hyperthyroidism and orbital manifestations. Research to test the effects of the modification of the gut microbiota are only at the beginning. Further studies are eagerly awaited.

Acknowledgement Open Access funding provided by Projekt DEAL.

Compliance with ethical standards

Conflict of interest Authors conduct clinical studies with the following companies: Horizon Pharma USA, Inc., Immunovant Sciences GmbH, Swiss SeraDiaLogistics (SDL) and QD Laser, Japan. The authors declare that they have no conflict of interest.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. R.S. Bahn, Current insights into the pathogenesis of Graves’ ophthalmopathy. Horm. Metab. Res. 47, 773–778 (2015)
2. T.F. Davies, T. Ando, R.Y. Lin et al. Thyrotropin receptor-associated diseases: from adenomatous to Graves disease. J. Clin. Investig. 115, 1972–1983 (2005)
3. R.S. Bahn, Thyrotropin receptor expression in orbital adipose/connective tissues from patients with thyroid-associated ophthalmopathy. Thyroid 12, 193–195 (2002)
4. S. Kumar, S. Iyer, H. Bauer et al. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in Graves’ orbital fibroblasts: inhibition by an IGF-1 receptor blocking antibody. J. Clin. Endocrinol. Metab. 97, 1681–1687 (2012)
5. S. Kumar, S. Nadeem, M.N. Stan et al. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves’ ophthalmopathy. J. Mol. Endocrinol. 46, 155–163 (2011)
6. S. Kumar, R. Schiefer, M.J. Coenen et al. A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves’ orbital preadipocyte fibroblasts. Thyroid 20, 59–65 (2010)
7. A. Eckstein, J. Esser, S. Mattheis et al. [Graves’ Orbitopathy]. Klin. Monbl Augenheilkd. 233, 1385–1407 (2016)
8. C.C. Krieger, S. Neumann, B. Marcus-Samuels et al. TSHR/IGF-1R Cross-Talk, not IGF-1R stimulating antibodies, mediates Graves’ ophthalmopathy pathogenesis. Thyroid 27, 746–747 (2017)
9. C.C. Krieger, R.F. Place, C. Bevilaqua, et al., Thyrotropin/IGF-1 receptor crosstalk in Graves’ ophthalmopathy pathogenesis. J. Clin. Endocrinol. Metab. 101, 2340–2347 (2016)
10. T.J. Smith, J. Janssen, Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr. Rev. 40, 236–267 (2019)
11. Y. Hiromatsu, D. Yang, T. Bednarczuk et al. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab. 85, 1194–1199 (2000)
12. S.J. Shan, R.S. Douglas, The pathophysiology of thyroid eye disease. J. Neuroophthalmol. 34, 177–185 (2014)
13. S. Plohn, B. Edelmann, L. Japtok et al. CD40 enhances sphingolipids in orbital fibroblasts: potential role of sphingosine-1-phosphate in inflammatory T-cell migration in Graves’ orbitopathy. Investig. Ophthalmol. Vis. Sci. 59, 5391–5397 (2018)
14. G.E. Gortz, M. Horstmann, B. Aniol et al. Hypoxia-dependent HIF-1 activation impacts on tissue remodeling in Graves’ ophthalmopathy–implications for smoking. J. Clin. Endocrinol. Metab. 101, 4834–4842 (2016)
15. S.M. Mclachlan, Y. Nagayama, B. Rapoport, Insight into Graves’ hyperthyroidism from animal models. Endocr. Rev. 26, 800–832 (2005)
16. B. Wiesweg, K.T. Johnson, A.K. Eckstein et al. Current insights into animal models of Graves’ disease and orbitopathy. Horm. Metab. Res. 45, 549–555 (2013)
17. Y. Nagayama, M. Kita-Furuyama, T. Ando et al. A novel murine model of Graves’ hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J. Immunol. 168, 2789–2794 (2002)
18. G.D. Chazenbalk, P. Pichurin, C.R. Chen et al. Thyroid-stimulating autoantibodies in Graves disease preferentially
recognize the free A subunit, not the thyrotropin holoreceptor. J. Clin. Investig. 110, 209–218 (2002).

19. C.R. Chen, P. Pichurin, Y. Nagayama et al. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J. Clin. Investig. 111, 1897–1904 (2003).

20. O. Saitoh, Y. Nagayama, Regulation of Graves’ hyperthyroidism with naturally occurring CD4+CD25+ regulatory T cells in a mouse model. Endocrinology 147, 2417–2422 (2006).

21. S. Costagliola, M.C. Many, J.F. Denef et al. Genetic immunization during development of an animal model of autoimmune thyroid eye disease. J. Immunol. 162, 4966–4974 (1999).

22. S. Costagliola, M.C. Many, M. Stalmans-Falys et al. Transfer of thyrotropins, with syngeneic spleen cells sensitized with the human thyrotropin receptor, to naive BALB/c and NOD mice. Endocrinology 137, 4637–4643 (1996).

23. M.C. Many, S. Costagliola, M. Detrait et al. Development of an animal model of autoimmune thyroid disease. J. Immunol. 125 (2019).

24. S.C. Ho, S.S. Goh, I.H. Kee et al. Effects of genetic immunization of Swiss outbred mice with human thyroid stimulating hormone receptor cDNA plasmids harboring gain-of-function mutations. J. Mol. Endocrinol. 38, 277–288 (2007).

25. S.X. Zhao, S. Tsui, A. Cheung et al. Orbital fibrosis in a mouse model of Graves’ disease induced by genetic immunization of thyrotropin receptor cDNA. J. Endocrinol. 210, 369–377 (2011).

26. G. Masetti, S. Moshkelgosha, H.L. Kohling, D. Covelli, J.P. Banga, U. Berchner-Pfannschmidt, M. Horstmann, S. Diaz-Cano, G.E. Goertz, S. Plummer, A. Eckstein, M. Ludgate, F. Biscarini, J. R. Marchesi Jr, INDIGO consortium, Gut microbiota in experimental murine model of Graves’ orbitopathy established in different environments may modulate clinical presentation of disease. Microbiome 6, 97 (2018).

27. U. Berchner-Pfannschmidt, S. Moshkelgosha, S. Diaz-Cano et al. Comparative assessment of female mouse model of Graves’ orbitopathy under different environments, accompanied by proinflammatory cytokine T cell responses to TSH-receptor antigen. Endocrinology, in revision (2020).

28. U. Flögel, A. Schlüter, C. Jacoby, S. Temme, J.P. Banga, A. Eckstein, J. Schrader, U. Berchner-Pfannschmidt, Multimodal assessment of orbital immune cell infiltration and tissue remodeling during development of Graves disease by 1 H19 F MRI. Magn. Reson. Med. 80, 711–718 (2018).

29. A. Schlüter, U. Flögel, S. Diaz-Cano et al. Graves’ orbitopathy occurs sex-independently in an autoimmune hyperthyroid mouse model. Sci. Rep. 8, 13096 (2018).

30. G. Masetti, S. Moshkelgosha, H.L. Kohling et al. Gut microbiota in experimental murine model of Graves’ orbitopathy established in different environments may modulate clinical presentation of disease. Microbiome 6, 97 (2018).

31. L. Goschel, C. Scheinecker, M. Bonelli, Treg cells in autoimmunity: from identification to Treg-based therapies. Semin. Immunopathol. 41, 301–314 (2019).

32. M. Romano, G. Fanelli, C.J. Albany et al. Past, present, and future of regulatory T Cell therapy in transplantation and autoimmunity. Front Immunol. 10, 43 (2019).

33. S. Plöhn, M. Hose, A. Schlüter, L. Michel, S. Diaz-Cano, U.B. Hendgen-Cotta, J.P. Banga, N.E. Bechrakis, W. Hansen, A. Eckstein, U. Berchner-Pfannschmidt, Fingolimod improves the outcome of experimental Graves’ disease and associated orbitopathy by modulating the autoimmune response to the thyroid-stimulating hormone receptor. Thyroid. 29, 1286–1301 (2019).

34. Q. Yuan, Y. Zhao, X. Zhu et al. Low regulatory T cell and high IL-17 mRNA expression in a mouse Graves’ disease model. J. Endocrinol. Invest. 40, 397–407 (2017).

35. F. Zhao, L. Wu, Y. Wang et al. Dihydrotestosterone regulates oxidative stress and immunosuppressive cytokines in a female BALB/c mouse model of Graves’ disease. Autoimmunity 52, 117–125 (2019).

36. J. Zhou, M. Bi, C. Fan et al. Regulatory T cells but not T helper 17 cells are modulated in an animal model of Graves’ hyperthyroidism. Clin. Exp. Med. 12, 39–46 (2012).

37. L. Liu, L. Wu, A. Gao et al. The Influence of dihydrotestosterone on the development of Graves’ disease in female BALB/c mice. Thyroid 26, 449–457 (2016).

38. J. Fassbender, H.P. Holthoff, Z. Li et al. Therapeutic effects of short cyclic and combined epitope peptides in a long-term model of Graves’ disease and orbitopathy. Thyroid 29, 258–267 (2019).

39. H.P. Holthoff, Z. Li, J. Fassbender et al. Cyclic peptides for effective treatment in a long-term model of Graves disease and orbitopathy in female mice. Endocrinology 158, 2376–2390 (2017).

40. L. Jansson, K. Vrolix, A. Jahraus et al. Immunotherapy with antigen peptides blocks the immune response to TSH receptor in HLA-DR transgenic mice. Endocrinology 159, 3446–3457 (2018).

41. S.H.S. Pearce, C. Dayan, D.C. Wraith, K. Barrett, N. Olive, L. Jansson, T. Walker-Smith, C. Carnegie, K.F. Martin, K. Boe-laert, J. Gilbert, C.E. Higham, I. Muller, R.D. Murray, P. Perros, S. Razvi, B. Vaidya, F. Wernig, G.J. Kahaly, Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves’ hyperthyroidism: a Phase I study. Thyroid 29, 1003–1011 (2019).

42. H. Rakov, K. Engels, G.S. Hones et al. Sex-specific phenotypes of hyperthyroidism and hypothyroidism in mice. Biol. Sex. Differ. 7, 36 (2016).